Molecule News and Research

RSS

New insight into multiple sclerosis

Scientists have blocked harmful immune cells from entering the brain in mice with a condition similar to multiple sclerosis.

8 Mar 2011

Solasia, ZIOPHARM enter license and collaboration agreement for darinaparsin product

ZIOPHARM Oncology, Inc., an oncology small molecule and synthetic biology drug development company, and Solasia Pharma K.K., a developer of Western oncology pharmaceuticals in-licensed for commercialization in Asian markets, announced today that they have entered into a license and collaboration agreement to develop and commercialize ZIOPHARM's darinaparsin product and related organic arsenic molecules in specified Pan-Asian/Pacific territories.

7 Mar 2011

New study unmasks molecule that can protect against epileptic seizure

For years brain scientists have puzzled over the shadowy role played by the molecule putrescine, which always seems to be present in the brain following an epileptic seizure, but without a clear indication whether it was there to exacerbate brain damage that follows a seizure or protect the brain from it. A new Brown University study unmasks the molecule as squarely on the side of good: It seems to protect against seizures hours later.

6 Mar 2011

Scientific symposium to examine new approaches to schizophrenia drug development

Despite significant investment in research and development by pharmaceutical companies, the last decade has seen a marked decline in the number of drugs developed and approved for schizophrenia. A multi-day symposium at the New York Academy of Sciences on Wednesday, March 9 - Friday, March 11 will convene world-leading experts in clinical, translational, and basic neuroscience to address this problem by examining novel, state-of-the-art approaches to schizophrenia drug development.

5 Mar 2011

Brain enzyme can restore even old, fading memories, say researchers

Even long after it is formed, a memory in rats can be enhanced or erased by increasing or decreasing the activity of a brain enzyme, say researchers supported, in part, by the National Institutes of Health.

4 Mar 2011

Study: Resveratrol can reduce body fat

For her thesis entitled Conjugated Linoleic Acid and Resveratrol: the effect of these functional ingredients on the metabolism of triglycerides and adiposity, Nutrition and Obesity research team member at the University of the Basque Country, Ms Arrate Lasa, studied the fat-reducing effect of CLA and resveratrol.

4 Mar 2011

SERS nanosubstrates revolutionize medical diagnostics

Gold-coated substrates of gallium nitride with specifically formed surface, developed by researchers from the Institute of Physical Chemistry of the Polish Academy of Sciences and the Institute of High Pressure Physics of the PAS display worldwide unique properties. Thanks to these new substrates, an extremely sensitive SERS analytical technique, capable of detecting even single molecules, after decades of waiting in specialized laboratories has finally got a chance to widespread and revolutionize medical diagnostics.

4 Mar 2011

Infinity commences IPI-926 Phase 2 clinical trial in rare, life-threatening bone cancer

Infinity Pharmaceuticals, Inc. today announced the initiation of a randomized, double-blind Phase 2 clinical trial to evaluate the safety and efficacy of IPI-926 compared to placebo in patients with metastatic or locally advanced, inoperable chondrosarcoma. The trial is expected to enroll over 100 patients worldwide.

3 Mar 2011

New insight: p53 protein controls molecular crossroads in glucose metabolic pathway

The gene for the protein p53 is the most frequently mutated in human cancer. It encodes a tumor suppressor, and traditionally researchers have assumed that it acts primarily as a regulator of how genes are made into proteins.

3 Mar 2011

Novel study deepens understanding of how chromosome replication works

A novel study from the Swedish medical university Karolinska Institutet has deepened the understanding of how chromosome replication, one of life's most fundamental processes, works.

3 Mar 2011

Groundbreaking discovery in lymphoma research

BC Cancer Agency scientists have discovered that a single gene, CIITA, is implicated in almost 40 per cent of primary mediastinal B-cell lymphomas and 15 per cent of all Hodgkin lymphoma cases.

3 Mar 2011

Omeros identifies orphan GPCR compounds associated to pancreatic cancer, cognitive disorders

Omeros Corporation today announced that it has identified compounds that interact selectively with two orphan G protein-coupled receptors linked to pancreatic cancer and cognitive disorders.

3 Mar 2011

U-M scientists identify potential target to treat aggressive prostate cancer

Researchers at the University of Michigan Comprehensive Cancer Center have identified a potential target to treat an aggressive type of prostate cancer. The target, a gene called SPINK1, could be to prostate cancer what HER2 has become for breast cancer.

3 Mar 2011

Achillion fourth quarter revenue is $2 million for three months ended December 31, 2010

Achillion Pharmaceuticals, Inc., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the three and twelve months ended December 31, 2010.

2 Mar 2011

Glycogen study findings shed light on possible route to treat Lafora disease

Indiana University scientists have solved a perplexing mystery regarding one of the body's main energy storage molecules, in the process shedding light on a possible route to treatment of a rare but deadly disease in teenagers.

2 Mar 2011

Neuralstem announces initiation of NSI-189 Phase Ia trial for major depressive disorder

Neuralstem, Inc. announced that the first subject was dosed yesterday in a Phase Ia trial to evaluate the safety of its drug, NSI-189, which is being developed for the treatment of major depressive disorder and other psychiatric indications. NSI-189 is the lead compound in Neuralstem's neurogenerative small molecule drug platform. This phase of the trial is in healthy volunteers and seeks to determine the maximum tolerated single dose.

2 Mar 2011

QLT fourth quarter revenues decrease 7.3% to $10.0 million

QLT Inc. today reported financial results for the fourth quarter ended December 31, 2010 and full year 2010 as well as issued its guidance for 2011. Unless specified otherwise, all amounts are in U.S. dollars and in accordance with U.S. GAAP.

1 Mar 2011

New research reveals how maternal antibodies block immune response to measles virus

New research that reveals how maternal antibodies block an immune response to the measles virus is a first step toward improving current childhood vaccination practices, scientists say.

1 Mar 2011

Researcher identifies substance that inhibits cancer growth by activating 'dark genome'

A research study coordinated by Manel Esteller, researcher at Bellvitge Biomedical Research Institute (IDIBELL) has identified a substance that inhibits cancer growth by activating the so‑called "dark genome" (or non‑coding DNA) and micro‑RNA molecules. The study appears this week in the journal Proceedings of the National Academy of Sciences (PNAS).

1 Mar 2011

Research uncovers new details about protein interactions in retina

Science fiction novelist and scholar Issac Asimov once said, "The most exciting phrase to hear in science, the one that heralds new discoveries, is not 'Eureka!' but 'That's funny.' " This recently rang true for an international team of researchers when they observed something they did not expect.

1 Mar 2011

Molecule News and Research

New insight into multiple sclerosis

Solasia, ZIOPHARM enter license and collaboration agreement for darinaparsin product

New study unmasks molecule that can protect against epileptic seizure

Scientific symposium to examine new approaches to schizophrenia drug development

Brain enzyme can restore even old, fading memories, say researchers

Study: Resveratrol can reduce body fat

SERS nanosubstrates revolutionize medical diagnostics

Infinity commences IPI-926 Phase 2 clinical trial in rare, life-threatening bone cancer

New insight: p53 protein controls molecular crossroads in glucose metabolic pathway

Novel study deepens understanding of how chromosome replication works

Groundbreaking discovery in lymphoma research

Omeros identifies orphan GPCR compounds associated to pancreatic cancer, cognitive disorders

U-M scientists identify potential target to treat aggressive prostate cancer

Achillion fourth quarter revenue is $2 million for three months ended December 31, 2010

Glycogen study findings shed light on possible route to treat Lafora disease

Neuralstem announces initiation of NSI-189 Phase Ia trial for major depressive disorder

QLT fourth quarter revenues decrease 7.3% to $10.0 million

New research reveals how maternal antibodies block immune response to measles virus

Researcher identifies substance that inhibits cancer growth by activating 'dark genome'

Research uncovers new details about protein interactions in retina

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News